Oral Anti-inflammatory LYT-100 Well-tolerated in Healthy People

Oral Anti-inflammatory LYT-100 Well-tolerated in Healthy People

312688

Oral Anti-inflammatory LYT-100 Well-tolerated in Healthy People

LYT-100 (deupirfenidone), an experimental oral therapy containing a similar active ingredient to Esbriet, was well-tolerated at all tested doses — and did not reach the maximum tolerated dose or MTD — in a Phase 1 trial conducted in healthy volunteers. PureTech Health, which is developing LYT-100 for idiopathic pulmonary fibrosis (IPF) and other diseases involving inflammation and tissue scarring, hopes this therapy will ease lung function decline in patients without the digestion-related side effects common with…

You must be logged in to read/download the full post.